帕金森病认知障碍相关皮层神经退变的影像学生物标志物
本研究纳入53例认知正常帕金森病患者、32例轻度认知障碍患者和35例痴呆患者,同期进行结构MRI、扩散加权MRI和[18F]FDG PET,比较三种模态检测皮层改变的能力。结果显示[18F]FDG PET对帕金森病痴呆和轻度认知障碍的诊断准确性最高,扩散指标可能是有前景的MRI替代方案。
要点
- [18F]FDG PET对帕金森病痴呆(AUC=0.89±0.05)和轻度认知障碍(AUC=0.78±0.05)诊断准确性最高。
- 扩散加权MRI对帕金森病痴呆诊断性能优异(AUC=0.87±0.06),对轻度认知障碍亦有显著性能(AUC=0.71±0.09)。
- 结构MRI区分轻度认知障碍与认知正常者准确性差(AUC=0.57±0.10)。
核心结论
- 在测试的模态中,[18F]FDG PET检测帕金森病认知障碍相关皮层改变最准确,尤其在早期阶段。
- 扩散测量可能代表一种有前景的基于MRI的替代方案。
研究设计与样本
- 研究纳入53例认知正常帕金森病患者、32例帕金森病轻度认知障碍患者和35例帕金森病痴呆患者,同期进行结构MRI、扩散加权MRI和[18F]FDG PET。
- 提取神经解剖图谱中52个皮层区域的灰质体积、平均扩散率和标准化摄取值比值,采用ANCOVA模型评估组间差异,并应用交叉验证机器学习方法识别最能指示痴呆状态模态特异性脑区,通过受试者工作特征分析评估诊断准确性。
主要发现
- 结构MRI显示颞叶和后顶叶萎缩可区分帕金森病痴呆与认知正常者(AUC=0.77±0.07),但区分轻度认知障碍与认知正常者准确性差(AUC=0.57±0.10)。
- 扩散加权MRI在内侧颞叶显示最明显扩散率改变,对帕金森病痴呆诊断性能优异(AUC=0.87±0.06),对轻度认知障碍性能较温和但仍显著(AUC=0.71±0.09)。
- [18F]FDG PET显示后枕区显著低代谢,对帕金森病痴呆(AUC=0.89±0.05)和轻度认知障碍(AUC=0.78±0.05)诊断准确性最高。
- 统计比较中,[18F]FDG PET(p<0.001)和扩散加权MRI(p<0.031)检测帕金森病痴呆和轻度认知障碍均优于结构MRI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Imaging biomarkers bear great promise for improving the diagnosis and prognosis of cognitive impairment in Parkinson's disease (PD). We compared the ability of three commonly used neuroimaging modalities to detect cortical changes in PD patients with mild cognitive impairment (PD-MCI) and dementia (PDD). METHODS: 53 cognitively normal PD patients (PD-CN), 32 PD-MCI, and 35 PDD underwent concurrent structural MRI (sMRI), diffusion-weighted MRI (dMRI), and [18F]FDG PET. We extracted grey matter volumes (sMRI), mean diffusivity (MD, dMRI), and standardized uptake value ratios ([18F]FDG PET) for 52 cortical regions included in a neuroanatomical atlas. We assessed group differences using ANCOVA models and further applied a cross-validated machine learning approach to identify the modality-specific brain regions that are most indicative of dementia status and assessed their diagnostic accuracy for group separation using receiver operating characteristic analyses. RESULTS: In sMRI, atrophy of temporal and posterior-parietal areas allowed separating PDD from PD-CN (AUC = 0.77 ± 0.07), but diagnostic accuracy was poor for separating PD-MCI from PD-CN (0.57 ± 0.10). dMRI showed most pronounced diffusivity changes in the medial temporal lobe, which provided excellent diagnostic performance for PDD (AUC = 0.87 ± 0.06), and a more modest but still significant performance for PD-MCI (AUC = 0.71 ± 0.09). Finally, [18F]FDG PET revealed pronounced hypometabolism in posterior-occipital regions, which provided the highest diagnostic accuracies for both PDD (AUC = 0.89 ± 0.05) and PD-MCI (AUC = 0.78 ± 0.05). In statistical comparisons, both [18F]FDG PET (p < 0.001) and dMRI (p < 0.031) outperformed sMRI for detecting PDD and PD-MCI. CONCLUSION: Among the tested modalities, [18F]FDG PET was most accurate for detecting cortical changes associated with cognitive impairment in PD, especially at early stages. Diffusion measurements may represent a promising MRI-based alternative.
引用
- Silva-Rodríguez J, Labrador-Espinosa MÁ, Castro-Labrador S, et al. Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson's disease. Eur J Nucl Med Mol Imaging. 2025. PMID: 39888421. doi:10.1007/s00259-025-07070-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。